Literature DB >> 11205154

Lessons from studies of antigen-specific T cell responses in Multiple Sclerosis.

R Martin1, B Bielekova, B Gran, H F McFarland.   

Abstract

Multiple Sclerosis (MS) is considered a T cell-mediated autoimmune disease of central nervous system myelin. Based on elegant experiments in an animal model of MS, experimental allergic encephalomyelitis (EAE), a number of myelin proteins and peptides derived from these can induce inflammatory demyelinating lesions. Recent studies with transgenic mice expressing human HLA-DR molecules and a myelin basic protein (MBP)-specific T cell receptor as well as data from a phase II clinical trial with an altered peptide ligand based on MBP peptide (83-99) provide convincing evidence that the pathogenetic concepts which largely stem from the above EAE studies are valid in MS, too.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205154     DOI: 10.1007/978-3-7091-6301-6_26

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  4 in total

Review 1.  Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

Authors:  Robert S Fujinami; Matthias G von Herrath; Urs Christen; J Lindsay Whitton
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis.

Authors:  Jan D Lünemann; Sandra Rückert; Florian Kern; Uwe Wendling; Ruud van der Zee; Hans D Volk; Frauke Zipp
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 3.  Autoimmune T-cell reactivity to myelin proteolipids and glycolipids in multiple sclerosis.

Authors:  Judith M Greer
Journal:  Mult Scler Int       Date:  2013-11-07

Review 4.  Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure.

Authors:  Navid Manouchehri; Victor H Salinas; Negar Rabi Yeganeh; David Pitt; Rehana Z Hussain; Olaf Stuve
Journal:  Front Neurol       Date:  2022-03-31       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.